Enzo Biochem, Inc.
ENZB · OTC
7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | 0.01 | -0.42 |
| FCF Yield | -46.19% | -54.61% | -17.06% | -2.58% |
| EV / EBITDA | -1.10 | 0.13 | -7.77 | 49.70 |
| Quality | ||||
| ROIC | -15.86% | -29.50% | -26.47% | 4.53% |
| Gross Margin | 45.86% | 37.24% | 39.20% | 45.51% |
| Cash Conversion Ratio | 1.01 | -1.82 | 0.91 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -33.21% | -35.86% | 12.09% | 13.20% |
| Free Cash Flow Growth | 32.54% | -98.07% | -395.48% | 79.07% |
| Safety | ||||
| Net Debt / EBITDA | 5.85 | 3.60 | 0.07 | 2.74 |
| Interest Coverage | -49.83 | -17.68 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.53 | 2.46 | 4.22 | 5.07 |
| Cash Conversion Cycle | 160.90 | 138.21 | 81.81 | 57.38 |